LGL leukemia. Since these mutations are present in less than half of the patients they cannot completely explain LGL leukemogenesis. A better mechanistic understanding of leukemic LGL survival will allow future consideration of a more targeted therapeutic approach than the current practice of immunosuppressive therapy.
Introduction
Initially described in 1985, Large Granular Lymphocyte (LGL) leukemia belongs to the rare chronic mature lymphoproliferative disorders of the T/NK lineage.
1 Two subtypes of LGL disorders were proposed in 1993 : T-LGL leukemia and aggressive NK cell leukemia. 2 The WHO recognized this classification scheme in 2001. Chronic NK-cell lymphocytosis was identified in 2008 as a provisional entity to differentiate it from the much more aggressive form of NK-cell leukemia. 3, 4 The most recent WHO version did not modify this classification scheme but did highlight discovery of Stat mutations described in 2012 (table 1) . 5, 6 T-LGL leukemia and chronic NK cell lymphocytosis share the same clinical and biological presentation as well as treatment options. 2, 7, 8, 9 Pathogenesis of the disease is dominated by a clonal expansion of LGL resistant to activation induced cell death (AICD) due to constitutive survival signaling. This review will describe topics concerning diagnosis, pathogenesis, current and future therapy of this rare disease.
Epidemiology
LGL leukemia accounts for 2-5% of chronic lymphoproliferative disorders in North
America and Europe and up to 5-6% in Asia. 2 Recently, the overall age-standardized incidence based on the national Dutch registry has been reported as 0.72 per 1,000,000 person-per year. 10 The incidence of LGL leukemia does not differ between male and female. Indolent T-LGL leukemia is the most frequent form of the disease representing around 85 % of the cases whereas chronic NK cell lymphocytosis is estimated at less than 10% of cases.
Aggressive NK LGL leukemia is mainly seen in Asia, comprising less than 5% of the
LGL disorders. It affects younger patients and is associated with EBV infection: the prognosis of this rare entity is very poor due to refractoriness to chemotherapy.
11,12
Diagnosis A definite diagnosis of LGL leukemia requires finding evidence of an expanded clonal T or NK cell LGL population.
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9
/l) have a clonal disorder. 9, 14, 15, 16 Leukemic LGL are easily identified on blood smears by their specific morphology;
however they are not cytologically distinguishable from normal reactive cytotoxic lymphocytes. They display a large size (15-18μ), an abundant cytoplasm containing typical azurophilic granules and a reniform or round nucleus with mature chromatin (Fig 1 A) . Blood smears must be examined carefully in cases of normal lymphocyte counts and in rare cases in which the clonal lymphocytes do not present with typical
LGL morphology.
LGL excess in bone marrow (> 10% LGL) is detected in the majority of cases.
(Figure 1B)
Immunophenotyping T-LGL leukemias show a constitutive mature post-thymic phenotype. In the vast majority of cases, T-LGL leukemia shows a CD3+, TCR αβ+, CD4-, CD5 dim , CD8+, CD16+, CD27-,CD28-, CD45R0-, CD45RA+, CD57+ phenotype which represents a constitutively activated T cell phenotype (Fig 2A) . 17, 18, 19 CD3+/CD56+ T-LGL leukemias may have a more aggressive behavior associated with Stat5b mutations. 20, 21 A rare subset of LGL leukemia is CD4+ with or without coexpression of CD8. Patents with this LGL leukemia subtype almost never have cytopenias, splenomegaly or autoimmune phenomena 22, 23 , and clonal LGL seem to be driven by CMV. 24 Recently, it was found that Stat5b mutations are frequent in this LGL subtype.
25
T-LGL leukemic cells are characterized by a terminal-effector memory phenotype defined by the expression of CD45RA and lack of CD62L expression. 26 Leukemic
LGL constitutively express IL2 Rβ (p75, CD122) but not IL2 Rα (p55, CD25).
27,28
Few cases are TCR γ δ +/CD4-/CD8-.
29,30
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31,32
Restricted KIR expression is often seen in both in T and NK LGL leukemia.
19,33

Clonality
Evidence of T-LGL clonality is routinely assessed using TCR γ -PCR analyses. Deep sequencing of TCR has demonstrated a restricted diversity of TCR repertoire. 34 Vβ TCR gene repertoire analysis can also be ascertained using flow cytometry (FCM) and serves as presumptive evidence for clonality. The ECOG prospective clinical trial suggested that a particular Stat3 mutation, Y640F, predicted response to initial therapy with methotrexate. 48 The first evidence of Stat5b mutations in human disease was discovered in LGL leukemia, but this mutation is not frequent (2%). 20 The N642H mutation in particular was associated with a more aggressive disease and a unusual CD3+CD56+ phenotype.
49
Marrow Features
The diagnosis of LGL leukemia as discussed above is readily established using blood studies, so that marrow aspirate/biopsy is not routinely recommended as part of initial evaluation. However, marrow evaluation can be helpful when the diagnosis is not straight-forward (eg LGL count not increased). Such studies are also of value when considering other diseases that are part of the differential, including MDS or aplastic anemia or when considering the diagnosis of pure red cell aplasia (PRCA) as potential etiology of profound anemia in patients with LGL leukemia.
Individual or small clusters of
LGLs may be sometimes identified. They are difficult to identify as they mimick granulocytic or monocytic precursors. As LGL infiltration of marrow is often a subtle finding, trephine biopsy with immunohistochemistry is recommended. 7,50,51,52 A "grey zone" where the diagnosis of LGL leukemia is not certain, should be considered in cases of low LGL count, or even lymphopenia associated with unexplained cytopenia in which the diagnosis can be easily missed LGL leukemia could partly explain the development of autoantibodies and clonal Bcell malignancies observed in this disease. 64 The associated comorbid conditions are reported in 
Pathogenesis of LGL Leukemia
A model of LGL leukemia pathogenesis is shown in Figure 5. LGL leukemia is at the intersection of a clonal lymphoproliferative disease, chronic inflammation, and autoimmunity. We hypothesize that an unknown antigen is the initial activating event, resulting in oligoclonal LGL expansion. Such chronic and persistent antigen exposure leads to Stat3 activation and emergence of a dominant clone. A shift from oligoclonal to clonal dominance is supported by serial studies of T cell repertoire utilization. 37 Somewhat surprisingly, clonal drift was observed with emergence over time of a different Vbeta clone in 37% of patients. 37 We speculate that clonal drift results from emergence of LGL clones recognizing different epitopes/peptides of the same chronic antigen. This theory could also explain the observation of clonal T cell
LGL populations seen in patients with chronic NK lymphocytosis as well as emergence of a new NK clone in patient with established T cell LGL leukemia.
74
LGL leukemia is characterized by profound dysregulation of the normal process of AICD. The fundamental pathogenic feature of LGL leukemia is activation of a survival network which keeps the leukemic LGL alive and functioning as killer cells .
75
The central hub of this survival network is Stat3. We hypothesize that activating mutations of Stat3 support clonal dominance by causing a higher level of LGLs. 91 Dysregulation of PI3K/Akt pathway Activated Akt is observed in leukemic LGL. Pro-inflammatory proteins RANTES, IL-18 and MIP-1b which activate PI3K pathway, are upregulated in LGL patients. 62 Increased activity of the PI3K-AKT signaling axis has been found in T-LGL cells and participated in apoptosis inhibition. LGL leukemia.
93
Dysregulation of sphingolipid rheostat in LGL leukemia Molecular expression profile analysis in LGL leukemia shows a predominant expression of pro-survival sphingolipids like S1P. 94 Sphingosine kinase 1 (SphK1) which converts sphingosine into SP1 is increased in LGL leukemia and SphK1 inhibition leads to leukemic LGLs apoptosis. SP1 binding to SP1R activates pro survival signal through ERK1/2 signaling. 95 Moreover, expression of S1P receptor, mainly S1PR5, is increased in LGL leukemia.
96,97
PROGNOSIS
T and chronic NK-LGL leukemia are considered indolent diseases. The vast majority of patients will eventually need treatment at some point during disease evolution.
Disease related deaths are mainly due to severe infections which occur in less than 10% of the patient population. 10,15,98 Overall survival at 10 years is close to 70%.
12
Conversely, the prognosis of aggressive NK LGL leukemia is very poor since patients are refractory to treatment. The most clinical experience has been reported using low-dose methotrexate, cyclophosphamide, and cyclosporine as single agents (see below).
Supportive therapy
Supportive care could be considered for patients suffering from anemia or neutropenia using EPO or G-CSF, respectively. However, such treatment does not address the underlying illness. G-CSF delivered as a single agent may be effective in rapidly increasing ANC. This could be of some value in the setting of patients with episodes of severe febrile neutropenia in which a rapid neutrophil response would be desirable. However, G-CSF is not effective in all LGL leukemia patients. Of note, G-CSF may induce exacerbation of splenomegaly and articular symptoms. 99, 100 Therapy with EPO in LGL leukemia patients has been reported only infrequently and with disappointing results.
15
First line therapy
Immunosuppressive therapy is the foundation of treatment for LGL leukemia based on the rationale that leukemic LGL represent constitutively activated cytotoxic lymphocytes.
First line therapy relies on use of single immunosuppressive oral agents such as methotrexate (MTX, 10mg/m²/week), cyclophosphamide (100 mg per day), or
For personal use only. on January 26, 2017. by guest www.bloodjournal.org From 13 cyclosporine (CyA, 3 mg/kg per day). A minimum of 4 months of therapy is required before assessing response. Since the initial publication on the efficacy of MTX, this drug has been considered until now as the best first line option, mainly for neutropenic patients. 101 Oral cyclophosphamide has been preferentially used in patients with predominant anemia and particularly PRCA.
60,102
Based on retrospective studies, the overall response rate (ORR) appears quite broad ranging from 21% to 85% (median around 50%), with similar responses to each of the 3 drugs, making comparison difficult. The complete response rate is relatively low, around 21% for MTX, 33% for cyclophosphamide, and less than 5% for CyA. The results of the first large prospective study of immunosuppressive agents in LGL leukemia was recently reported. 48 Fifty-five patients received MTX at first line and non-responders were switched to cyclophosphamide. The ORR was 38% in step 1 (which is lower compared to the results of the large retrospective studies) and 64% in step 2. These data indicate that a high proportion of patients may respond to cyclophosphamide even after having failed to respond to MTX. 15,100 As discussed earlier, Stat3 Y640F mutation may be predictive biomarker for response to methotrexate but this observation needs validation in a larger cohort of patients. An important randomized trial (NCT01976182) investigating first line MTX versus cyclophosphamide is ongoing in France will hopefully determine the best choice of initial therapy in this disease.
In case of failure of primary therapy, a switch between MTX and cyclophosphamide should be considered. In our practice, CyA is reserved for patients failing both drugs.
Both MTX and CyA are maintained indefinitely as long as these medications are reasonably tolerated and disease response is maintained. Long term use and monitoring of low dose MTX follows guideline recommendations of its use in RA.
Hepatic (hepatitis) and lung dysfunction (hypersensitivity pneumonitis) may occur requiring regular evaluation of liver tests and chest X-ray. Our recommendation is to The effects of prednisone as single agent in the treatment of LGL leukemia are not convincing but may decrease some inflammatory symptoms related to RA and in rare cases it may transiently improve neutropenia.
Second line therapy
It is difficult to make any treatment recommendations for patients refractory to the first line agents, because of the rarity of the disease and general absence of prospective data. To the authors' knowledge there is only one ongoing clinical trial in the United States, which investigates alentuzumab. 110 The US author's practice is to refer refractory patients for consideration of participation in this study being conducted at the NIH.
Clinical experience using a number of different options in a smaller number of patients has been reported for LGL leukemia patients and these could be considered for refractory patients. These results are summarized below:
i) Purine analogs. Rituximab, the specific antiCD20 monoclonal antibody, has been paradoxically used in patients having both RA and LGL leukemia. It was suggested that eradication of B cell expansion and autoimmune antigens could have led to eradication of reactive
LGL clones. In our opinion, this is not a reasonable option for LGL leukemia. LGL leukemia. Of interest, low dose MTX was recently identified as a very active inhibitor of Jak/Stat pathway, perhaps now explaining its efficacy in LGL leukemia. 119 However, in complete responders, STAT3 mutated sub clones are still detected.
47
There are recent exciting data concerning Jak3 pathway inhibition. Jak3 is now considered as a target for immunosuppression. Tofacitinib citrate (CP690550), a Jak3
For personal use only. on January 26, 2017. by guest www.bloodjournal.org From 16 specific inhibitor has demonstrated impressive activity in refractory RA. 120, 121 Recently, 9 patients with refractory LGL leukemia and RA were treated with Tofacitinib citrate. Hematologic response was observed in 6/9 cases, with improvement in neutropenia observed in 5/7 patients. 122 Since NFκB is constitutively active in T-LGL, Bortezomib could be considered a promising agent for investigation in LGL leukemia as supported by demonstrating efficacy in the LGL leukemia model of IL15 transgenic mice. 88 In LGL leukemia, proapoptotic signals (ceramide) are downregulated and prosurvival signals (S1PR5) are up-regulated 95, 96 . We showed that FTY720, a S1PR agonist, induced apoptosis of LGL cells and that C6-ceramide encapsulated in nanoliposomes led to apoptosis in an NK-LGL rat leukemia model by targeting survivin. A trial of Ceramide Nanoliposomes is ongoing in patients with advanced solid tumors (NCT02834611) and this could be a potential therapeutic candidate for LGL leukemia.
Conclusions
It appears that immunosuppressive agents such as MTX, cyclophosphamide and
CyA are limited in their capacity to eradicate the LGL clone and induce long lasting remission. Due to lack of prospective comparative clinical trials, there is no way to yet decide which one of these three agents is best proposed as first line therapy.
There is an urgent unmet need to develop better therapeutics for LGL leukemia, as 
STAT3 wt
For personal use only. on January 26, 2017. by guest www.bloodjournal.org STAT3 is activated and may acquire a mutation. Chronic antigen stimulation leads to expansion of one dominant (monoclonal) cytotoxic lymphocyte population (all are outlined in black signifying the monoclonal population). Three outcomes occur. In panel 1, production of inflammatory cytokines (starburst shapes representing: IFN-γ, IL-8, IL-10, IL1-β, IL-12p35, IL-18, IL1Ra, RANTES, MIP1-α, MIP1-β) causes symptoms such as neutropenia, anemia, and fatigue, and can also cause autoimmune disease such as rheumatoid arthritis (RA). In panel 2, the functional killer cells release cytotoxic granules containing perforin and granzyme B (purple dots); this leads to the same outcomes as in 1. In panel 3, the STAT3-mediated survival network results in a persisting clone due to profound dysregulation of apoptosis, including resistance to Fas/FasL mediated death and upregulation of Mcl-1.
For personal use only. on January 26, 2017. by guest www.bloodjournal.org From LGL leukemia cells are resistant to Fas mediated apoptosis. Soluble Fas (sFas) acts as a decoy receptor able to inhibit Fas-dependent apoptosis. Increased level of an inhibitory protein named c-FLIP contributes to the DICS formation defect. Jak/Stat3 pathway: Stat3 is constitutively activated in LGL leukemia and is responsible for the transcription of Bcl2 and Mcl1 protein expression. Inhibition of Stat3 restores apoptosis of LGL cells whatever Stat3 mutation status witch implies that Stat3 mutation is not itself mandatory to explain LGL clonal expansion. SOCS3 witch inhibits Jak/Stat3 pathway is significantly decreased in LGL leukemia. Survival signal: LGL leukemia shows a predominant expression of pro-survival sphingolipids (S1P). SphK1 which converts sphingosine into SP1 is increased in LGL leukemia and SphK1 inhibition leads to leukemic LGLs apoptosis. SP1 binding to SP1R activate pro survival signal through ERK1/2 signaling. Moreover, expression of S1P receptor, mainly S1PR5, is increased in LGL leukemia. Ras-Raf-1-MEK1-ERK, PI3K/AKT pathway are upregulated in LGL leukemia and they inhibition lead to LGL apoptosis. Increased activity of the PI3K-AKT signaling axis is found in T-LGL cells and participate to apoptotic inhibition. NFκB activity is upregulated in LGL leukemia. NFκB acts downstream of the PI3K-AKT pathway to prevent apoptosis through Mcl-1 independently of Stat3. A recurrent non-synonymous mutation in the gene encoding an NFκB signaling inhibitor, TNFAIP3, was found in 8% of LGL leukemia patients. IL15 and PDGF: IL15 promotes myc expression through NFKB pathway (model of IL15 transgenic mouse). IL15 is associated to an increase of global DNA methylation level in LGL leukemia through DNMT3A upregulation. The down regulation of miR-29 is responsible for the up regulation of DNMT3A witch induce methylation of the tumor suppressor gene Ibd4. 
